Finance

Lists
1795:TPE
Lotus Pharmaceutical Co Ltd
NT$196.00
-0.25%
(-0.50) 1D
Aug 24, 1:30:01 PM GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 1795...
Open
NT$202.00
High
NT$202.50
Low
NT$196.00
Mkt. cap
52.31B
Avg. vol.
1.61M
Volume
2.26M
Dividend
1.31%
Quarterly dividend
NT$0.64
Ex-dividend date
Aug 11, 2025
P/E ratio
13.60
52-wk high
NT$369.50
52-wk low
NT$170.50
EPS
NT$14.41
No. of employees
1K
Open
NT$202.00
High
NT$202.50
Low
NT$196.00
Mkt. cap
52.31B
Avg. vol.
1.61M
Volume
2.26M
Dividend
1.31%
Quarterly dividend
NT$0.64
Ex-dividend date
Aug 11, 2025
P/E ratio
13.60
52-wk high
NT$369.50
52-wk low
NT$170.50
EPS
NT$14.41
No. of employees
1K
News stories
From web sources and news partners
About Lotus Pharmaceutical Co Ltd
CEOPetar Vazharov
Employees1.1K
Founded1966
Headquarters-
SectorPharmaceutical industry
Websitelotuspharm.com.tw
Previous reportsAll values in TWD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in TWD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
4.77B
6.26B
8.64B
8.81B
Cost of goods sold
2.04B
2.80B
4.26B
4.08B
Cost of revenue
2.04B
2.80B
4.26B
4.08B
Research and development expenses
447.99M
-33.26M
279.59M
246.02M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.10B
1.70B
2.14B
2.15B
Operating expense
1.54B
1.67B
2.43B
2.40B
Total operating expenses
3.58B
4.47B
6.69B
6.48B
Operating income
1.19B
1.80B
1.96B
2.33B
Other non operating income
-35.38M
22.65M
111.63M
-157.17M
EBT including unusual items
1.83B
1.32B
725.90M
990.25M
EBT excluding unusual items
1.22B
1.44B
727.99M
990.25M
Income tax expense
397.56M
194.58M
158.70M
348.00M
Effective tax rate
21.70%
14.78%
21.86%
35.14%
Other operating expenses
-
-
-
-
Net income
1.43B
1.12B
567.20M
642.25M
Net profit margin
30.07%
17.91%
6.56%
7.29%
Earnings per share
5.53
4.32
2.00
2.46
Interest and investment income
27.63M
31.75M
33.26M
28.46M
Interest expense
-123.20M
-489.98M
-1.21B
-1.21B
Net interest expenses
-95.58M
-458.22M
-1.17B
-1.19B
Depreciation and amortization charges
-
-
-
-
EBITDA
1.53B
2.21B
2.54B
3.02B
Gain or loss from assets sale
-702.00K
4.03M
2.09M
-1.38M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps